Inve India ▾

Remus Pharma. share price & results

Remus Pharma.· Healthcare

Results to
Mar 2026
Latest analysed call
Q2 FY26
Ownership as of
Sept 2026

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue47.0 ₹ crore+14.6% YoYQuarterly, as filedQuarter to Mar 2026Revenue from operations as filed.
Operating margin32.0 %−4.0 pts YoYOperating profit / revenueQuarter to Mar 2026For the quarter; a change is in percentage points.
Net profit13.0 ₹ crore+18.2% YoYQuarterly, as filedQuarter to Mar 2026Profit after tax as filed.
Return on equityUnavailable−1.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.
Free cash flow margin0.50 %−0.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable−153.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Mar 2026

Guidance

What management said, and what became of it

1 of 3 judged targets kept · 4 open · verdicts reflect calls analysed to Q2 FY26.

Remus Pharma. management guidance track record on Inve: 7 targets tracked across analysed earnings calls (1 achieved, 2 missed, 4 open).

TargetOriginal wordingSaidLatest callVerdict
Revenue Growthwe will see a sustainable growth in the revenue, which we will see in the next coming year [FY26] (not exorbitant like 191%)
Call transcript, Q4 FY25 · 19 May 2025		Q4 FY25Q2 FY26:H1 FY26 revenue grew at a sustainable 47% YoY, aligning perfectly with the narrative of normalizing growth.
Call transcript, Q2 FY26 · 11 Nov 2025		Achieved
B2C Business Shareby end of this year [FY25], we will have at least 25% to 30% of B2C business
Call transcript, Q4 FY25 · 19 May 2025		Q4 FY25Q2 FY26:H1 FY26 actual is only 13%. Management revised the target down to 18-20% by the end of FY26.
Call transcript, Q2 FY26 · 11 Nov 2025		Missed
Semaglutide-like Commercializationthose sales and revenues will also be coming pretty soon, probably H2 [FY26] is what we are aiming.
Call transcript, Q4 FY25 · 19 May 2025		Q4 FY25Q2 FY26:Not explicitly mentioned, but the timeline (H2 FY26) has not yet arrived.
Call transcript, Q2 FY26 · 11 Nov 2025		On Track

Source: Inve Guidance Tracker for Remus Pharma. · to Q2 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Remus Pharma.'s 7 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 4 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹880.45 −1.33% · −₹11.85

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +28.8% 1Y

₹0.6k₹0.7k₹0.8k₹0.9k₹1.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 11 Nov 2025

1Y: ₹683.4 on 24 Oct 2025 → ₹880.45. High ₹1,020.75 (14 Oct 2026), low ₹582.85 (9 Mar 2026).

Previous close
₹892.3
Market cap
₹1.1k Cr
52-week range
₹582.85 – ₹1,020.75
One year
+31.57%
Price to earnings (FY ending Mar 2026)
28.55×
Return on equity (FY ending Mar 2026)
12.13%

Overview

Symbol
NSE:REMUS
Exchange
NSE
Currency
INR

How the price took the results

close before → close after

Q2 FY26
−1.0%
11 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Remus Pharma.

Free account: one company. Everything above stays public.

Write why you follow Remus Pharma. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Remus Pharma.

Guides on how to read this kind of business and the numbers that matter.